Harrison.ai has been awarded three FDA breakthrough device designations for its imaging AI solutions, including a tool for obstructive hydrocephalus triage.
Key Details
- 1Harrison.ai received three FDA breakthrough device designations.
- 2One designation is for a triage/prioritization AI solution for obstructive hydrocephalus.
- 3The solution is among only 13% of FDA breakthrough devices to achieve 510(k) marketing authorization.
- 4It is one of only two radiology FDA breakthrough devices to become eligible for Medicare’s NTAP.
- 5The FDA program aims to speed up innovation and clinical access to critical devices.
Why It Matters
FDA breakthrough status highlights a product's potential to address unmet clinical needs, and rapid regulatory pathways can accelerate adoption in radiology practice. Harrison.ai's achievement signals growing validation and support for advanced imaging AI in critical care.
Source
Radiology Business
Related News
•AuntMinnie
Study: Computer Vision Models Best LLMs in Chest CT Breast Abnormality Detection
Computer vision models (CVMs) surpass large language models (LLMs) in accurately labeling incidental breast abnormalities on chest CT scans.
•Radiology Business
Private Equity Backs AIRS Medical to Expand MRI AI Globally
TA Associates is investing in AIRS Medical to accelerate its global expansion of AI-powered MRI efficiency solutions.
•Cardiovascular Business
Radiology Maintains Lead in FDA-Cleared AI Algorithms, Cardiology Follows
Radiology remains the top specialty for FDA-cleared AI, with cardiology as a strong second, particularly in cardiovascular imaging.